Abstract
Introduction
The optimal treatment for young patients with high-risk newly diagnosed multiple myeloma (NDMM) remains a challenge.
Methods
We retrospectively evaluated 58 NDMM patients younger than 55 years treated in our center from 2010 to 2021 with the current recommended protocols.
Results
After a median follow-up of 48 months, median overall survival (OS) was not reached; however, approximately 25% of them died within 4 years after diagnosis. Advanced disease stage, presence of extramedullary disease, elevated LDH, and less than very good remission before autologous hematopoietic stem-cell transplantation adversely affected patient survival. Based on these factors, we created a risk-assessment scoring system that sufficiently discriminated young NDMM patients at risk of poor outcome. The 4-year OS was superior for patients with zero to two factors to those with three to five factors (86% vs 44%, p<0.001).
Conclusion
The proposed scoring system could be reliably used at diagnosis and at interim disease evaluation in aiming for personalized treatment for young NDMM patients.
Data Sharing
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Acknowledgments
The authors wish to thank Sudair Pharmaceutical Company for assistance with manuscript publication.
Author Contributions
All authors made a significant contribution to the work reported, whether is in conception, study design, execution, acquisition of data, analysis and interpretation, or all these areas, took part in drafting, revising, or critically reviewing the article, gave final approval to the version to be published, have agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work.
Disclosure
The authors declare no competing interests.